Skip to contentP
Precision Biosciences Inc
P
DTILPrecision Biosciences Inc Q3 2024 · 10-Q
Revenue$576.00K$576.00K−95.6% vs Q3 2023 Net Income-$16.43M-$16.43MN/M vs Q3 2023 EPS Diluted-$2.25-$2.25N/M vs Q3 2023 Operating Income-$21,275,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Precision Biosciences Inc · CIK 1357874 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$5,951,000N/M Margins · derivedOperating margin-3693.6%−3599.3 pt vs Q3 2023
Net margin-2851.6%−2790.0 pt vs Q3 2023
ended Sep 30, 2024 · filed Nov 4, 2024 · 35 d after period end